Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a conjugated chimeric (human-mouse) monoclonal antibody targeting carcinoembryonic antigen (CEA), chemically linked to fluorescein for detection purposes, likely for in vitro or ex vivo diagnostic applications such as immunohistochemistry or flow cytometry. The chimeric antibody design reduces immunogenicity compared to purely murine antibodies. While there is extensive literature on chimeric anti-CEA monoclonal antibodies (e.g., cT84.66) labeled with radioisotopes for imaging and therapy in clinical trials[1], there is no specific published information in the provided search results regarding a fluorescein conjugate of this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chimeric anti-carcinoembryonic antigen monoclonal antibody-fluorescein conjugate.